Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher W Ryan

Showing results (31-40 of 113) with videos related to

Pageof 12
Sort By:
Urology|July 28, 2007
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapyChristopher W Ryan, Dezheng Huo, James W Stallings, et al.
Oncology Nursing Forum|July 7, 2015
Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate CancerKerri M Winters-Stone, Nathan Dieckmann, Gianni F Maddalozzo, et al.
Cancer|July 14, 2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasMargaret von Mehren, Cathryn Rankin, John R Goldblum, et al.
Clinical Genitourinary Cancer|May 27, 2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapyTomasz M Beer, Bryan Goldman, Craig R Nichols, et al.
Medicine and Science in Sports and Exercise|February 7, 2014
Skeletal response to resistance and impact training in prostate cancer survivorsKerri M Winters-Stone, Jessica C Dobek, Jill A Bennett, et al.
BJU International|June 8, 2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidChristopher W Ryan, Dezheng Huo, Kathryn Bylow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerWalter M Stadler, Dingcai Cao, Nicholas J Vogelzang, et al.
The Journal of Urology|September 23, 2003
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerWalter M Stadler, Dezheng Huo, Christopher George, et al.
Cancer Medicine|December 24, 2018
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adultsBrittany Wippel, Kenneth R Gundle, Theresa Dang, et al.
Clinical Genitourinary Cancer|June 10, 2022
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell CarcinomaZizhen Feng, Brendan D Curti, David I Quinn, et al.
Pageof 12

Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Urology|July 28, 2007
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapyChristopher W Ryan, Dezheng Huo, James W Stallings, et al.
Oncology Nursing Forum|July 7, 2015
Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate CancerKerri M Winters-Stone, Nathan Dieckmann, Gianni F Maddalozzo, et al.
Cancer|July 14, 2011
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomasMargaret von Mehren, Cathryn Rankin, John R Goldblum, et al.
Clinical Genitourinary Cancer|May 27, 2008
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapyTomasz M Beer, Bryan Goldman, Craig R Nichols, et al.
Medicine and Science in Sports and Exercise|February 7, 2014
Skeletal response to resistance and impact training in prostate cancer survivorsKerri M Winters-Stone, Jessica C Dobek, Jill A Bennett, et al.
BJU International|June 8, 2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidChristopher W Ryan, Dezheng Huo, Kathryn Bylow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerWalter M Stadler, Dingcai Cao, Nicholas J Vogelzang, et al.
The Journal of Urology|September 23, 2003
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerWalter M Stadler, Dezheng Huo, Christopher George, et al.
Cancer Medicine|December 24, 2018
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adultsBrittany Wippel, Kenneth R Gundle, Theresa Dang, et al.
Clinical Genitourinary Cancer|June 10, 2022
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell CarcinomaZizhen Feng, Brendan D Curti, David I Quinn, et al.
Pageof 12